Bipolar I Disorder: Symptoms, Diagnosis, and Treatment
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Bipolar I disorder is a clinically defined mood disorder in which a person has experienced at least one manic episode. Mania involves a distinct, sustained change in mood and energy or activity that is sufficiently severe to cause marked impairment, require hospitalization, or involve psychotic features. Depressive episodes are common, sometimes prolonged and disabling, but a major depressive episode is not necessary for the bipolar I diagnosis. The determining event is mania, assessed in the context of a person's longitudinal clinical history. National Institute of Mental Health VA/DoD clinical guideline
Understanding bipolar I requires more than identifying an unusual mood. Clinicians examine a change from baseline, episode duration, the combination of symptoms, observable behavior, sleep and activity patterns, consequences for functioning, and possible medical or substance-related explanations. Treatment also follows the phase of illness: acute mania, bipolar depression, and prevention of new episodes call for different therapeutic decisions. This guide brings together diagnosis, symptoms, differential diagnosis, medication and psychotherapy evidence, safety, recovery, and questions that arise in clinical care. NICE guideline CANMAT/ISBD update
For additional clinical context, see Types of Bipolar Disorder: Bipolar I, Bipolar II, Cyclothymia, and Other Forms and Bipolar II Disorder: Symptoms, Diagnosis, and Treatment.
What is bipolar I disorder?
Bipolar I disorder is a recognized psychiatric diagnosis characterized by at least one lifetime manic episode. Mania is an episode of abnormally and persistently elevated, expansive, or irritable mood together with increased energy or goal-directed activity. In standard diagnostic practice, the period usually lasts at least seven days and is present most of the day nearly every day; a shorter episode can qualify when hospitalization is necessary. The episode must produce marked impairment, require hospitalization, or include psychosis. It cannot be more appropriately explained by a substance or another medical condition. NIMH clinical overview VA/DoD diagnostic and treatment guideline
A person's mood between episodes may return close to their usual baseline, although residual symptoms, sleep disturbance, cognitive difficulty, and problems in relationships or work can persist. The disorder commonly follows a recurrent course, with different individuals experiencing different combinations of mania, depression, and symptom-free intervals. Neither a single day's elevated mood nor a period of high productivity establishes bipolar I disorder. NIMH NICE
The word 'bipolar' refers to the possibility of clinically significant mood episodes of opposite polarities. It does not mean that everyone alternates predictably between two emotional states, changes mood several times a day, or spends equal time manic and depressed. A person may seek treatment during depression and report an earlier manic episode only when a clinician asks about the full life course. NIMH
The defining manic episode: symptoms and diagnostic threshold
Changes in mood, energy, and activity
During mania, mood can become unusually euphoric or expansive, but irritability and agitation may dominate instead. Clinicians look for a noticeable rise in energy or activity that occurs alongside the mood change, rather than relying on subjective happiness alone. The individual may initiate numerous projects, make unusually ambitious plans, become intensely socially active, or feel compelled to keep moving. Family members, coworkers, or friends may recognize the change before the person experiencing it does. NIMH VA/DoD
Characteristic symptoms include inflated self-esteem or grandiosity; a markedly reduced need for sleep; much more talk than usual or pressure to keep talking; racing thoughts or rapid shifts between ideas; distractibility; increased goal-directed activity or psychomotor agitation; and unusually risky activities with potential financial, sexual, interpersonal, or other harmful consequences. A clinically significant manic episode generally includes three of these additional symptoms, or four when mood is only irritable, within the defined episode and severity requirements. Diagnostic counting always belongs within a broader clinical evaluation. VA/DoD NIMH
Reduced need for sleep versus insomnia
One particularly informative sign is sleeping very little while feeling rested, energized, or able to function without usual fatigue. This differs from insomnia, in which a person wants to sleep but struggles to do so and often feels tired. Reduced need for sleep is neither universal nor diagnostic by itself; stimulants, shift work, other psychiatric states, medical illness, and sleep deprivation can complicate interpretation. Significant sleep loss can also destabilize someone who already has bipolar disorder. NIMH NICE
Judgment, impairment, and psychotic symptoms
Mania can disrupt insight and judgment. Someone may make financial commitments they ordinarily would question, abandon employment responsibilities, drive recklessly, engage in unsafe sexual behavior, or become unusually confrontational. Others may experience such severe disorganization that basic daily activities become difficult. These are possible manifestations, not a universal profile or a basis for moral judgment. Severity and change from the person's prior functioning are central to assessment. NIMH NICE
Psychotic features can occur during severe manic or depressive episodes. Delusions may involve implausible beliefs about extraordinary power or identity; hallucinations can occur as well. Psychotic symptoms during mania indicate an episode of manic severity, rather than hypomania. Clinicians must also assess whether psychosis occurs only during mood episodes or outside them, because that distinction affects differential diagnosis. Psychosis accompanied by danger, profound disorganization, or inability to care for basic needs warrants urgent clinical evaluation. NIMH VA/DoD
Mania, hypomania, and ordinary mood changes
Hypomania and mania can share elevated or irritable mood, increased activity, rapid speech, decreased need for sleep, and other symptoms. A hypomanic episode generally lasts at least four consecutive days, is an unequivocal change from the person's usual functioning, and is observable to others. By definition, it does not cause the marked impairment or need for hospitalization that characterizes mania, and it has no psychotic features. If psychosis is present, the episode is manic. VA/DoD NIMH
A person can have hypomanic symptoms at other points in their life and still meet criteria for bipolar I when they have also experienced a genuine manic episode. Conversely, a brief burst of optimism after good news, excitement about a new project, variable energy from caffeine, or irritability under stress cannot be called mania merely because it looks intense. Clinicians establish an episodic syndrome and the associated functional consequences. NIMH
Bipolar I versus bipolar II and cyclothymic disorder
Bipolar I disorder requires a manic episode. Bipolar II disorder requires at least one hypomanic episode and at least one major depressive episode, with no lifetime manic episode. Cyclothymic disorder involves a prolonged pattern of recurring hypomanic and depressive symptoms that do not fulfill the complete episode criteria during the relevant periods. Other specified and unspecified bipolar diagnoses cover presentations that do not fully match those patterns. NIMH
Bipolar II is sometimes called 'milder bipolar disorder,' a description that confuses the severity of elevated episodes with the burden of the entire illness. Hypomania is less severe than mania by diagnostic definition, but bipolar II depression and associated disability can be substantial. Equally, bipolar I does not mean a person is manic most of the time. The categories are defined by lifetime episode patterns rather than a single severity ladder. NIMH CANMAT/ISBD
Depressive episodes in bipolar I
Many people with bipolar I experience episodes of major depression lasting at least two weeks. Symptoms may include persistent low mood or loss of interest, reduced energy, sleep and appetite changes, difficulty concentrating, guilt or worthlessness, slowed movement or agitation, and thoughts of death or suicide. Bipolar depression may interfere with work, relationships, personal care, and medical adherence. Depression often occupies a major share of long-term illness burden even though mania establishes the bipolar I category. NIMH CANMAT/ISBD
Bipolar depression can resemble major depressive disorder when viewed at a single appointment. The difference depends on whether a manic episode has occurred at another time in the person's life. This makes systematic questioning about past periods of elevated energy and unusual activity essential when someone presents with depression. Antidepressant choices also differ, because antidepressant monotherapy is generally discouraged in bipolar I depression and should not be extrapolated from unipolar depression treatment protocols. VA/DoD CANMAT/ISBD
Mixed features, rapid cycling, and episodes with psychosis
Mixed features
A mood episode may include symptoms associated with the opposite polarity. For example, a person with manic elevation may report pronounced depressive symptoms, or a person in bipolar depression may also show activation and racing thoughts. Contemporary diagnostic terminology uses the 'with mixed features' specifier when its criteria are satisfied. Mixed presentations often require careful assessment of agitation, impulsivity, psychotic symptoms, suicidal thinking, and medication-related activation. Simply feeling happy and sad on the same day is not sufficient for a mixed-features diagnosis. NIMH NICE
Rapid cycling
Rapid cycling is a course specifier used when at least four qualifying mood episodes occur within a 12-month period, with appropriate separation or polarity change. It does not mean emotional changes every few minutes or hours. Accurate classification therefore requires a timeline of episodes, their duration, remission periods, and treatments. Substance use, thyroid conditions, and medication effects may complicate apparent cycling. NIMH VA/DoD
Psychotic features
Mood-congruent psychotic features may reflect the themes of the active episode, such as grandiose beliefs during mania or guilt and ruin during depression. Mood-incongruent symptoms can also occur. Because psychosis can appear in multiple psychiatric or medical conditions, clinicians evaluate timing, consciousness, substance exposure, and other symptoms instead of automatically treating any hallucination as proof of bipolar disorder. NIMH
How bipolar I disorder is diagnosed
The lifetime episode history
Diagnosis is based on a structured clinical account of symptom onset, episode duration, change from baseline, impairment, recovery, and recurrence. A clinician asks what the person was doing, how much they slept, whether others noticed a change, whether hospitalization occurred, and whether delusions or hallucinations were present. They also ask about depressive episodes, anxiety, substances, family history, existing medications, and prior psychiatric diagnoses. Collateral information from relatives or other trusted witnesses can clarify an episode when the patient's recall or insight is incomplete, provided confidentiality and consent are handled appropriately. NICE VA/DoD
The strongest information may be longitudinal. Old emergency records, hospitalization notes, medication histories, and calendars can reveal an earlier manic episode that a depression-focused interview misses. The assessment should distinguish a clear episode from a lifelong temperament, a persistent attention problem, or a response to a situational crisis. If symptoms occur in association with a prescribed drug or stimulant, the clinician examines whether they represent an adverse effect, a substance-induced mood condition, or an episode that persists beyond the substance's physiological effects. VA/DoD NIMH
Medical evaluation and screening tools
A physical examination and targeted testing may be appropriate to identify contributors such as thyroid abnormalities, neurological illness, medication effects, and intoxication or withdrawal. The selection of tests depends on symptoms and clinical history; there is no blood test, brain scan, or genetic profile that independently confirms bipolar I disorder in an individual patient. Evaluation may involve primary care and a psychiatrist, with an urgent pathway for severe symptoms. NIMH VA/DoD
Questionnaires can flag experiences that deserve further exploration but cannot establish the diagnosis by score alone. A positive screen may reflect another condition, substance effects, or symptoms below the manic threshold; a negative screen can miss episodes that are poorly remembered. A clinician interprets any tool in conjunction with a full interview and lifetime course. NICE VA/DoD
What to bring to a clinical appointment
Useful information includes an approximate timeline of elevated and depressed periods; sleep duration and perceived need for sleep; examples of decisions or behavioral changes; current and previous medications; alcohol or drug exposure; relevant medical conditions; family psychiatric history; and records of emergency visits or hospital admissions. If the person agrees, observations from someone who knew them during the suspected episode may add important detail. Bringing these notes supports a more accurate assessment without turning self-tracking into self-diagnosis. NIMH NICE
What else can resemble bipolar I disorder?
Major depressive disorder can look similar during a depressive episode, but the lifetime history of mania changes the diagnosis. Attention-deficit/hyperactivity disorder may involve distractibility, impulsivity, and activity, often with a persistent developmental pattern rather than the distinct onset and offset of mania. Borderline personality disorder can involve affective instability and impulsive behavior related to interpersonal contexts; it may also coexist with a bipolar disorder. The relevant question is how symptoms unfold across time, what they are linked to, and whether full mood episodes occur. NIMH VA/DoD
Schizophrenia-spectrum and other psychotic disorders become important differential considerations when hallucinations or delusions occur outside a clear mood episode. Anxiety disorders and obsessive-compulsive disorder can involve agitation, restlessness, intrusive thinking, or changes in sleep without a manic episode. Substance-related conditions, stimulants, corticosteroids, endocrine disorders, and sleep or neurological conditions also deserve consideration. The clinician assesses each possibility on its own evidence and may diagnose co-occurring conditions when criteria are independently met. NIMH VA/DoD
For a focused discussion of the intersection with intrusive thoughts and repetitive behavior, see the existing English Hub comparison OCD vs Bipolar Disorder. That related topic concerns differential features; it does not replace an assessment of bipolar I disorder. NIMH
Causes, mechanisms, and risk factors
Genetic liability and environmental influences
Bipolar disorders involve complex genetic susceptibility. Risk is higher among close biological relatives of affected individuals, but inheritance is probabilistic; no single gene determines that a particular person will develop the disorder. Multiple genetic variants interact with developmental and environmental influences, and relatives may have different outcomes even with substantial shared biology. Family history is useful during assessment but is not a substitute for an episode-based diagnosis. NIMH
Stressful experiences, disruptions of sleep and daily schedules, and substance exposure may contribute to the timing or course of episodes for some individuals. These relationships do not establish one universal cause or imply that a specific life event created the disorder. Mechanistic models include circadian regulation, neurotransmission, cellular signaling, and brain-network processes, but none yet yields a routine, individually decisive diagnostic biomarker. NIMH CANMAT/ISBD
Sleep and circadian rhythms
Sleep deserves attention both as a symptom and as an element of relapse planning. Reduced sleep need may signal emerging mania; disrupted schedules can also increase vulnerability in someone with a known bipolar disorder. Stable routines for sleep, waking, meals, and activity can support treatment, but lifestyle regularity alone is not a replacement for prescribed acute or maintenance care. NIMH NICE
Who develops bipolar I disorder?
Bipolar disorder commonly begins during late adolescence or early adulthood, although initial symptoms may emerge earlier or later. Presentation can vary substantially by age, health conditions, and developmental stage. Epidemiological estimates differ according to diagnostic definition, study population, and whether bipolar I, bipolar II, or broader bipolar-spectrum conditions are included. A single prevalence figure for all bipolar disorders should not be represented as the rate of bipolar I alone. NIMH
Children and adolescents need developmentally appropriate assessment because irritability, attention symptoms, and behavioral dysregulation have many causes. Older adults require review of medical and neurological explanations, medication sensitivity, and possible interactions. Pregnancy planning and postpartum symptoms require specialized psychiatric and obstetric coordination because relapse risks and medication safety considerations change during those periods. General adult trial results should not simply be assumed to apply equally to each of these groups. NICE CANMAT/ISBD
Treatment of bipolar I disorder: three clinical goals
The aims of treatment are to resolve dangerous or disabling acute symptoms, address bipolar depressive episodes, and reduce future episodes while preserving functioning and quality of life. The choice of treatment depends on current phase, severity, prior response, physical health, other medications, pregnancy potential, patient preference, adherence barriers, and available follow-up. A medicine shown effective for acute mania is not automatically proven effective for bipolar depression, and an agent useful in long-term prevention is not necessarily the preferred rescue treatment for immediate agitation. CANMAT/ISBD VA/DoD
Acute mania and emergency stabilization
Acute mania may require prompt psychiatric assessment, a lower-stimulation environment, structured sleep support, and medication aimed at reducing manic symptoms. Guideline-supported options include lithium and several second-generation antipsychotics, such as quetiapine, risperidone, aripiprazole, or asenapine, with selection and combinations tailored to severity and the relevant guideline. Divalproex or valproate has a role in selected contexts but requires attention to reproductive safety, interactions, and monitoring. Highly agitated patients, those with psychosis, and people unable to maintain safety or basic care may need emergency services or hospitalization. CANMAT/ISBD VA/DoD NICE
Short-term medications for agitation or sleep may be used in supervised acute care, but they address immediate symptoms rather than constituting a complete long-term bipolar treatment plan. Clinicians monitor response, sedation, movement symptoms, cardiac or metabolic risks where relevant, and the patient's ability to participate in care. Electroconvulsive therapy may be considered for severe or treatment-resistant episodes or situations requiring a rapid clinical response, with its indications evaluated by the treating team. VA/DoD NIMH
Bipolar depression
A bipolar depressive episode needs treatments supported for bipolar depression rather than simply applying usual major depressive disorder protocols. Guideline-supported approaches for bipolar I depression include selected second-generation antipsychotics and, depending on the clinical context, lithium, lamotrigine, and other phase-specific combinations. The CANMAT/ISBD hierarchy includes quetiapine and lurasidone in appropriate regimens, while NICE specifies choices such as quetiapine and an olanzapine–fluoxetine combination. Individual approvals, availability, contraindications, prior response, and recommendations differ by jurisdiction and guideline. CANMAT/ISBD NICE
Lamotrigine is important in long-term prevention, particularly for depressive recurrence, but it is not a rapid antimanic treatment and slow titration limits its suitability when an immediate effect is needed. Antidepressants are not recommended as stand-alone treatment for bipolar I depression because of concern about manic switching and course destabilization. Their adjunctive use remains a specialist, case-specific judgment; short-term trials and observational evidence answer different questions about switching risk and do not eliminate the need for monitoring. CANMAT/ISBD NIMH 2025 systematic review
Maintenance treatment and relapse prevention
After improvement from an acute episode, continuing treatment can reduce the likelihood and severity of recurrence. Lithium has a substantial evidence base across longer-term bipolar care; maintenance regimens may also use quetiapine, lamotrigine, aripiprazole, divalproex, or other agents depending on the polarity of past episodes and an individual's previous benefit and tolerability. The best preventive choice differs for mania versus depression, and combinations may be necessary. Clinicians regularly reassess side effects, adherence, functioning, and emerging symptoms rather than treating remission as the end of care. CANMAT/ISBD NICE
Stopping effective medication can increase recurrence risk, particularly when discontinuation is abrupt. Any planned reduction or change should be supervised, gradual when appropriate, and accompanied by a relapse-monitoring plan. Some people need intensive follow-up during transitions, while others manage with scheduled outpatient reviews. Ongoing treatment can allow a person to study, work, maintain relationships, and pursue life goals even when the condition is recurrent. NICE NIMH
Medication benefits, limitations, and safety monitoring
Lithium
Lithium is used in the treatment and prevention of manic episodes and has important long-term evidence in bipolar disorder. It requires blood-level monitoring because its effective and potentially toxic concentrations are relatively close. Kidney function, thyroid function, calcium status, hydration, concurrent illnesses, and drug interactions matter throughout treatment. Common adverse effects can include tremor, thirst, increased urination, and gastrointestinal symptoms. The risk of toxicity rises with dehydration, certain kidney changes, and interacting drugs such as nonsteroidal anti-inflammatory drugs, diuretics, and some blood-pressure medicines. DailyMed lithium prescribing information NICE lithium guidance
Serious toxicity may present with marked vomiting or diarrhea, worsening tremor, unsteady walking, confusion, or other neurological symptoms and requires prompt medical evaluation. Lithium monitoring schedules and target concentrations must be individualized by the clinician; numerical examples from guidelines are not instructions for self-dosing. People taking lithium should consult their prescribing team when a febrile illness, dehydration, or a new medication raises concerns, and should not adjust or discontinue treatment independently. DailyMed lithium safety information NICE
Lamotrigine
Lamotrigine has a recognized place in maintenance treatment of bipolar I, particularly in relation to prevention of depressive episodes. It is not indicated as a rapid treatment for acute mania. One important hazard is serious skin rash, including Stevens–Johnson syndrome and toxic epidermal necrolysis. Risk can increase when initial doses are too high, titration is too fast, or valproate is co-prescribed. New rash during lamotrigine treatment requires immediate medical advice and evaluation under the prescribing guidance. DailyMed lamotrigine label CANMAT/ISBD
Medication interruptions and restarting can affect the safe titration schedule; the patient should contact the prescribing clinician rather than independently resuming a prior high dose. Lamotrigine may have interactions with certain other drugs, including valproate and some hormonal treatments. Selection in pregnancy or other special circumstances requires individualized consultation. DailyMed lamotrigine label
Valproate and divalproex
Valproate and divalproex can be used in selected cases of mania and maintenance treatment but require clinical attention to liver function, platelet counts, pancreatitis warnings, drug interactions, and other adverse effects. They carry major fetal risks, including congenital malformations and adverse neurodevelopmental outcomes. Regulatory restrictions differ between countries, and treatment decisions in anyone who could become pregnant require specialist risk counseling and consideration of alternatives. No one should stop a prescribed medication abruptly upon learning of these risks; urgent medication review is the appropriate next step. NICE safety recommendations CANMAT/ISBD
Second-generation antipsychotics
Several second-generation antipsychotics have evidence for specific phases of bipolar illness, but the indications are not interchangeable. Some are used in acute mania, others in bipolar depression, and some in maintenance. Depending on the drug, important risks include weight gain, changes in blood glucose or lipids, sedation, restlessness, movement-related adverse effects, and cardiovascular concerns. Before and during treatment, clinical guidelines recommend appropriate checks of weight, blood pressure, metabolic measures, adverse effects, and symptom response. CANMAT/ISBD NICE antipsychotic monitoring guidance
Antidepressants and other medications
Antidepressants require special care in bipolar I disorder. Treating bipolar depression with an antidepressant alone can be associated with manic switching or worsening of mood instability, and major guidelines advise against routine monotherapy. In a selected situation a specialist may consider an adjunctive antidepressant alongside mood-stabilizing treatment, with monitoring for emerging agitation, insomnia, hypomania, or mania. Decisions also depend on whether depressive symptoms include mixed features and on the person's prior treatment response. NIMH CANMAT/ISBD 2025 randomized-trial synthesis
Medication safety is a continuous process: establish the treatment target, monitor both symptoms and adverse events, review concurrent drugs and supplements, and update the plan as health circumstances change. Prescription decisions and dosing belong with the treating clinician, especially where kidney or liver disease, pregnancy, older age, or polypharmacy affects risk. NICE VA/DoD
Psychotherapy and psychosocial treatment
Psychotherapy is an evidence-supported adjunct to medication for many people with bipolar disorder. Interventions include bipolar-specific psychoeducation, cognitive behavioral therapy, family-focused therapy, and interpersonal and social rhythm therapy. They can help people recognize prodromal symptoms, manage stress, develop regular daily routines, address relationship strain, and practice collaborative relapse-prevention strategies. They do not replace urgent treatment of severe mania or psychosis. NIMH NICE
A systematic review and component network meta-analysis of 39 randomized clinical trials involving 3,863 participants found that structured adjunctive psychosocial interventions were associated with fewer recurrences than treatment as usual, although studies differed in participants, intervention components, and follow-up. Family, cognitive behavioral, and psychoeducational approaches showed useful signals; the evidence supports offering skills-based therapies alongside appropriate medical treatment while recognizing that no single format is best for everyone. JAMA Psychiatry systematic review
Therapeutic work can also address the psychosocial consequences of episodes: damaged trust, financial strain, missed education, changes in identity, shame, and difficulties returning to work. When a person is acutely ill, the level of involvement and timing should fit their current capacity. Family participation is guided by the person's preferences, confidentiality, and safety rather than assumed as universally desirable. NICE JAMA Psychiatry review
When is urgent help needed?
Urgent evaluation is warranted when a person develops sustained severe manic activation, escalating risky behavior, psychosis, profound sleep loss with behavioral deterioration, inability to meet basic needs, or suicidal thinking with possible intent or plan. Manic symptoms may impair judgment, and family members may need to seek professional advice even when the person does not recognize the severity of the episode. Severe depression with inability to eat, drink, or care for oneself also needs prompt assessment. NIMH VA/DoD
For immediate danger, contact local emergency services. In the United States, call or text 988 for the Suicide & Crisis Lifeline; outside the United States, use the local crisis or emergency service. While assistance is being arranged, prioritize a safer environment, support from trusted people, and direct communication with qualified professionals. Educational descriptions of bipolar I disorder cannot substitute for an emergency assessment. NIMH crisis and support information
Living with bipolar I: recovery and long-term functioning
A collaborative relapse-prevention plan
A practical plan identifies personal early warning signs, a baseline sleep-and-activity pattern, medications and monitoring appointments, crisis contacts, and agreed steps to take when changes are detected. Warning signs may differ across individuals: some notice earlier waking, unusually rapid speech, increased goal setting, irritability, or accelerated spending; others first experience depressive withdrawal and loss of interest. A timeline or mood journal can aid discussion with a clinician, especially after a new treatment or major life change. NIMH NICE
Long-term recovery also includes addressing physical health. Weight, metabolic health, activity, cardiovascular risk, and medication-related laboratory findings deserve routine assessment. Coordinated care can include primary care, psychiatry, psychological therapy, social support, employment assistance, and practical help with disrupted finances or housing. Treatment is most useful when it supports a person's goals, preferences, relationships, and autonomy as well as reducing recurrence. NICE VA/DoD
Work, relationships, and family support
An episode may strain communication and trust, create debts, interrupt education, or lead to conflict. These effects can persist after mood symptoms improve. Recovery can involve gradual return to responsibilities, agreed financial safeguards, access to leave or accommodations when appropriate, and respectful conversations about what support the person wants during future warning periods. Family and close supporters benefit from understanding the difference between a symptom pattern and the person's enduring values. NIMH NICE
Supporters can help by listening, encouraging follow-up, noticing meaningful departures from the person's baseline, and assisting with agreed practical tasks. They should also protect their own wellbeing and know when professional crisis services are needed. Decisions about treatment should remain collaborative when the person can participate; urgent safety procedures are reserved for situations in which risk and capacity demand them. NIMH
Special considerations across the lifespan
Adolescents and young adults
Earlier onset can affect schooling, developing identity, sleep patterns, family relationships, and substance exposure. Because irritability or hyperactivity also occurs in many nonbipolar conditions, diagnosis should carefully establish a distinct mood episode, observed changes, severity, and developmental context. Treatments selected for adults may have different safety evidence or regulatory status in younger populations. Family involvement and safeguards must fit age, capacity, and local law. NIMH CANMAT/ISBD
Older adults
When apparent mania begins later in life, clinicians give particular attention to medical or neurological conditions, medications, cognition, and drug interactions. Physical health monitoring becomes especially important with lithium, antipsychotics, and other long-term treatments. The treatment plan should reflect kidney function, frailty, falls risk, and the patient's preferences, rather than using a standard younger-adult regimen without reassessment. NICE CANMAT/ISBD
Pregnancy and the postpartum period
Pregnancy planning should trigger a specialist review of illness history, relapse risk, medications, and reproductive safety. The risks of untreated severe illness and the risks of individual medications must both be evaluated. Valproate has particularly important fetal safety concerns. Lithium, lamotrigine, and antipsychotics each raise different questions about monitoring, dose changes, exposure, and postpartum planning. Abrupt unsupervised discontinuation can create its own risks. Perinatal care should be coordinated between psychiatry and obstetric clinicians familiar with bipolar disorder. NICE CANMAT/ISBD
Common misconceptions about bipolar I
One misconception is that bipolar I always means frequent mood swings. In reality the diagnosis is based on distinct episodes meeting duration and severity criteria, often with substantial time between them. Another is that every person with bipolar I has psychosis; psychotic features occur in some severe episodes but are not universal. A third is that a person must have experienced major depression; a manic episode is sufficient for bipolar I when the remaining diagnostic requirements are met. NIMH
A further misconception is that manic behavior reveals someone's permanent character. Clinical symptoms can change judgment, energy, and behavior during an episode, yet accountability, repair, and recovery remain individualized processes. It is equally misleading to treat a diagnosis as a permanent forecast of incapacity: with individualized treatment, supportive relationships, follow-up, and attention to relapse prevention, many people improve functioning and quality of life. NIMH NICE
Frequently asked questions
Can you have bipolar I without ever having depression?
Yes. At least one manic episode is essential for the diagnosis, whereas a major depressive episode is common but not mandatory. A complete evaluation still asks about prior and future depression, mixed features, and other conditions. NIMH
Does a manic episode always last seven days?
The usual threshold is at least one week, but a shorter episode can meet the manic duration criterion when hospitalization is necessary. Severity, associated symptoms, marked functional impairment or psychosis, and exclusion of substance- or medical-induced presentations remain central. NIMH VA/DoD
Can someone have bipolar I and still seem completely well between episodes?
Yes. Interepisode recovery can be substantial. Some people nevertheless experience residual depression, sleep disturbance, anxiety, or functional difficulties, so follow-up may remain useful even when visible symptoms are minimal. Long-term management addresses recurrence risk as well as current symptoms. NIMH NICE
What is the difference between hypomania and mania?
Both can involve increased energy and elevated or irritable mood. Mania is defined by greater severity, such as marked impairment, hospitalization, or psychotic symptoms; hypomania does not reach that threshold. The usual minimum duration also differs. A clinical interview determines which, if either, occurred. NIMH VA/DoD
Can an online bipolar test diagnose bipolar I?
No. Screening questions may suggest that a professional should ask more about episodes, but diagnosis requires evaluation of duration, impairment, lifetime course, substance and medical explanations, and differential diagnoses. The same score can arise from different underlying problems. VA/DoD NIMH
Is bipolar I treated with antidepressants?
A specialist may sometimes prescribe an antidepressant as part of a carefully monitored combination, but antidepressants alone are generally not recommended for bipolar I depression. Treatments with evidence for the depressive phase and maintenance should be considered in their own right. Medication should never be started, stopped, or altered based on a general article. CANMAT/ISBD NIMH
Can bipolar I disorder be cured?
Current treatment aims at effective symptom control, reducing recurrence, protecting health, and maintaining a fulfilling life. Bipolar I is commonly recurrent and often needs long-term care; a period without episodes is valuable remission but does not prove that the underlying vulnerability has disappeared. NIMH NICE
What should someone do if they recognize early signs of mania?
Contact the treating clinician promptly, review the agreed relapse plan, and seek help from trusted supporters if appropriate. Escalating psychosis, dangerous behavior, inability to care for oneself, or thoughts of suicide warrant urgent or emergency assessment. Avoid making unsupervised medication changes. NICE NIMH
Related Articles
For a closer look at related diagnostic questions, read OCD vs Bipolar Disorder: What Is the Difference?, OCD and Bipolar Disorder: What Is the Connection?, and Neuroticism and Bipolar Disorder: Associations, State Effects, and Limits. Each article addresses a distinct, previously published English Hub search intent.
References
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD). (2023). The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence. Focus. DOI: 10.1176/appi.focus.20230009.
DailyMed / U.S. National Library of Medicine. (2026). Lamotrigine tablets: U.S. prescribing information, including serious skin rash warning. Official label.
DailyMed / U.S. National Library of Medicine. (2026). Lithium carbonate capsules: U.S. prescribing information, including toxicity and monitoring. Official label.
Miklowitz, D. J., et al. (2021). Adjunctive psychotherapy for bipolar disorder: A systematic review and component network meta-analysis. JAMA Psychiatry. Journal article.
National Institute for Health and Care Excellence (NICE). (2014; updated). Bipolar disorder: Assessment and management (CG185). Clinical guideline and recommendations.
National Institute of Mental Health (NIMH). (2025). Bipolar disorder (NIH Publication No. 25-MH-8088). Official clinical overview.
Switch to mania after acute antidepressant treatment for bipolar depression: A systematic review and network meta-analysis of randomized controlled trials. (2025). eClinicalMedicine, 87, 103413. DOI: 10.1016/j.eclinm.2025.103413.
U.S. Department of Veterans Affairs and U.S. Department of Defense (VA/DoD). (2023). VA/DoD clinical practice guideline for the management of bipolar disorder. Official guideline.